FDA Continues Next-Gen Sequencing Push With Two More Meetings
This article was originally published in The Gray Sheet
Executive Summary
The agency has scheduled two more workshops to inform its plans on regulating next-generation sequencing, including one meeting that will focus on oncology panels, and another that addresses questions about how sequencing results should be communicated to patients and providers.